Clinical Cancer Research, Vol 2, Issue 5 837-842, Copyright © 1996 by American Association for Cancer Research

ARTICLES

Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum

JJ Kavanagh, AP Kudelka, CG de Leon, D Tresukosol, M Hord, MB Finnegan, EE Kim, D Varma, A Forman, P Cohen, CL Edwards, RS Freedman and CF Verschraegen
Section of Gynecologic Medical Oncology, Division of Diagnostic Imaging, The University of Texas M.D. Anderson Cancer Center, Houston, USA.

We analyzed the efficacy and toxicity of docetaxel in patients with ovarian cancer who failed previous chemotherapy with platinum. Fifty-five patients with measurable ovarian cancer were entered in this Phase II study at The University of Texas M. D. Anderson Cancer Center. Treatment consisted of 100 mg/m2 docetaxel given i.v. every 3 weeks. Because of hypersensitivity reactions, premedication with steroids and antihistamine was initiated during the study. Twenty-two (40%) patients responded (there were 3 complete responders and 19 partial responders). Twenty-one (38%) patients had stable disease. The median survival was 10 months. The main toxicity was neutropenia (98% of patients), with 13 episodes of neutropenic fever. Cumulative fluid retention was the main reason for dose modification and required a combination of diuretics and steroids for palliation. Other side effects were alopecia (100%); anemia (87%); dermatitis (67%); gastrointestinal disorders (53%); stomatitis (49%); neurotoxicity (45%); excessive lacrimation (33%); and hypersensitivity reactions (11%), which in one case were life threatening (loss of consciousness, fluid resuscitation). Docetaxel as a single agent proved to be active in heavily pretreated ovarian cancer patients but is associated with significant side effects. Objective toxicity consisted mainly of neutropenia and fluid retention. Neutropenia was dose limiting and required therapy with granulocyte colony-stimulating factor. Fluid retention was improved but not eliminated by diuretics and corticosteroids. Additional studies of docetaxel in ovarian carcinoma are indicated to define the activity in relation to paclitaxel and in platinum combination therapy.

This article has been cited by other articles:

				G. Aravantinos, D. Bafaloukos, G. Fountzilas, C. Christodoulou, C. Papadimitriou, N. Pavlidis, H. P. Kalofonos, H. Gogas, P. Kosmidis, and M. A. Dimopoulos Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer Ann. Onc., July 1, 2003; 14(7): 1094 - 1099. [Abstract] [Full Text] [PDF]

				S. A. Cannistra, R. C. Bast Jr., J. S. Berek, M. A. Bookman, C. P. Crum, P. D. DePriest, J. E. Garber, W.-J. Koh, M. Markman, W. P. McGuire III, et al. Progress in the Management of Gynecologic Cancer: Consensus Summary Statement J. Clin. Oncol., May 15, 2003; 21(90100): 129s - 132. [Full Text] [PDF]

				P. A. Vasey Role of Docetaxel in the Treatment of Newly Diagnosed Advanced Ovarian Cancer J. Clin. Oncol., May 15, 2003; 21(90100): 136s - 144. [Abstract] [Full Text] [PDF]

				T. J. Herzog Update on the Role of Topotecan in the Treatment of Recurrent Ovarian Cancer Oncologist, October 1, 2002; 7(90005): 3 - 10. [Abstract] [Full Text] [PDF]

				C. F. Verschraegen, T. Sittisomwong, A. P. Kudelka, E. d. P. Guedes, M. Steger, T. Nelson-Taylor, M. Vincent, R. Rogers, E. N. Atkinson, and J. J. Kavanagh Docetaxel for Patients With Paclitaxel-Resistant Mullerian Carcinoma J. Clin. Oncol., July 14, 2000; 18(14): 2733 - 2739. [Abstract] [Full Text] [PDF]

				J. E. Groopman and L. M. Itri Chemotherapy-Induced Anemia in Adults: Incidence and Treatment J Natl Cancer Inst, October 6, 1999; 91(19): 1616 - 1634. [Abstract] [Full Text] [PDF]

				M. A. Bookman Extending the Platinum-Free Interval in Recurrent Ovarian Cancer: The Role of Topotecan in Second-Line Chemotherapy Oncologist, April 1, 1999; 4(2): 87 - 94. [Abstract] [Full Text]